Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 7/10

vs
industry
vs
history
Cash to Debt 0.19
NYSE:CHE's Cash to Debt is ranked lower than
57% of the 253 Companies
in the Global Medical Care industry.

( Industry Median: 0.33 vs. NYSE:CHE: 0.19 )
Ranked among companies with meaningful Cash to Debt only.
NYSE:CHE' s Cash to Debt Range Over the Past 10 Years
Min: 0.01  Med: 0.2 Max: 2.78
Current: 0.19
0.01
2.78
Equity to Asset 0.58
NYSE:CHE's Equity to Asset is ranked higher than
65% of the 248 Companies
in the Global Medical Care industry.

( Industry Median: 0.50 vs. NYSE:CHE: 0.58 )
Ranked among companies with meaningful Equity to Asset only.
NYSE:CHE' s Equity to Asset Range Over the Past 10 Years
Min: 0.36  Med: 0.52 Max: 0.61
Current: 0.58
0.36
0.61
Interest Coverage 48.15
NYSE:CHE's Interest Coverage is ranked higher than
75% of the 213 Companies
in the Global Medical Care industry.

( Industry Median: 7.76 vs. NYSE:CHE: 48.15 )
Ranked among companies with meaningful Interest Coverage only.
NYSE:CHE' s Interest Coverage Range Over the Past 10 Years
Min: 6.01  Med: 10.94 Max: 50.61
Current: 48.15
6.01
50.61
F-Score: 5
Z-Score: 8.17
M-Score: -3.14
WACC vs ROIC
12.78%
18.10%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 8/10

vs
industry
vs
history
Operating margin (%) 11.12
NYSE:CHE's Operating margin (%) is ranked higher than
61% of the 254 Companies
in the Global Medical Care industry.

( Industry Median: 6.84 vs. NYSE:CHE: 11.12 )
Ranked among companies with meaningful Operating margin (%) only.
NYSE:CHE' s Operating margin (%) Range Over the Past 10 Years
Min: 9.44  Med: 11.19 Max: 11.95
Current: 11.12
9.44
11.95
Net-margin (%) 6.77
NYSE:CHE's Net-margin (%) is ranked higher than
62% of the 254 Companies
in the Global Medical Care industry.

( Industry Median: 4.82 vs. NYSE:CHE: 6.77 )
Ranked among companies with meaningful Net-margin (%) only.
NYSE:CHE' s Net-margin (%) Range Over the Past 10 Years
Min: 4.97  Med: 6.22 Max: 7.14
Current: 6.77
4.97
7.14
ROE (%) 21.86
NYSE:CHE's ROE (%) is ranked higher than
83% of the 236 Companies
in the Global Medical Care industry.

( Industry Median: 9.67 vs. NYSE:CHE: 21.86 )
Ranked among companies with meaningful ROE (%) only.
NYSE:CHE' s ROE (%) Range Over the Past 10 Years
Min: 12.58  Med: 17.56 Max: 22.86
Current: 21.86
12.58
22.86
ROA (%) 12.30
NYSE:CHE's ROA (%) is ranked higher than
87% of the 254 Companies
in the Global Medical Care industry.

( Industry Median: 3.90 vs. NYSE:CHE: 12.30 )
Ranked among companies with meaningful ROA (%) only.
NYSE:CHE' s ROA (%) Range Over the Past 10 Years
Min: 6.21  Med: 9.64 Max: 12.88
Current: 12.3
6.21
12.88
ROC (Joel Greenblatt) (%) 151.16
NYSE:CHE's ROC (Joel Greenblatt) (%) is ranked higher than
91% of the 254 Companies
in the Global Medical Care industry.

( Industry Median: 18.74 vs. NYSE:CHE: 151.16 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
NYSE:CHE' s ROC (Joel Greenblatt) (%) Range Over the Past 10 Years
Min: 150.21  Med: 170.41 Max: 190.39
Current: 151.16
150.21
190.39
Revenue Growth (3Y)(%) 6.20
NYSE:CHE's Revenue Growth (3Y)(%) is ranked lower than
57% of the 181 Companies
in the Global Medical Care industry.

( Industry Median: 8.20 vs. NYSE:CHE: 6.20 )
Ranked among companies with meaningful Revenue Growth (3Y)(%) only.
NYSE:CHE' s Revenue Growth (3Y)(%) Range Over the Past 10 Years
Min: -15.9  Med: 11 Max: 42.9
Current: 6.2
-15.9
42.9
EBITDA Growth (3Y)(%) 8.10
NYSE:CHE's EBITDA Growth (3Y)(%) is ranked higher than
53% of the 154 Companies
in the Global Medical Care industry.

( Industry Median: 7.40 vs. NYSE:CHE: 8.10 )
Ranked among companies with meaningful EBITDA Growth (3Y)(%) only.
NYSE:CHE' s EBITDA Growth (3Y)(%) Range Over the Past 10 Years
Min: -31.4  Med: 9.8 Max: 52.3
Current: 8.1
-31.4
52.3
EPS Growth (3Y)(%) 11.10
NYSE:CHE's EPS Growth (3Y)(%) is ranked higher than
60% of the 133 Companies
in the Global Medical Care industry.

( Industry Median: 6.50 vs. NYSE:CHE: 11.10 )
Ranked among companies with meaningful EPS Growth (3Y)(%) only.
NYSE:CHE' s EPS Growth (3Y)(%) Range Over the Past 10 Years
Min: -15.4  Med: 11.9 Max: 56.8
Current: 11.1
-15.4
56.8
» NYSE:CHE's 10-Y Financials

Financials (Next Earnings Date: Est. 2017-07-26)


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow
Oprt. Cash Flow & Net Income

» Details

Guru Trades

Q4 2015

CHE Guru Trades in Q4 2015

Jeremy Grantham 23,900 sh (New)
Jim Simons 86,000 sh (+2429.41%)
Joel Greenblatt 85,164 sh (+442.45%)
John Hussman 52,000 sh (+30.00%)
Paul Tudor Jones Sold Out
Ken Fisher 549,589 sh (-0.79%)
Mario Gabelli 639,314 sh (-3.62%)
Keeley Asset Management Corp 15,005 sh (-22.85%)
Chuck Royce 56,100 sh (-45.94%)
» More
Q1 2016

CHE Guru Trades in Q1 2016

Jeremy Grantham 82,400 sh (+244.77%)
Jim Simons 148,200 sh (+72.33%)
Joel Greenblatt 86,834 sh (+1.96%)
Mario Gabelli 641,067 sh (+0.27%)
Chuck Royce 56,100 sh (unchged)
John Hussman Sold Out
Ken Fisher 549,268 sh (-0.06%)
Keeley Asset Management Corp 13,495 sh (-10.06%)
» More
Q2 2016

CHE Guru Trades in Q2 2016

Jeremy Grantham 114,877 sh (+39.41%)
Joel Greenblatt 106,927 sh (+23.14%)
Keeley Asset Management Corp 15,985 sh (+18.45%)
Mario Gabelli 644,007 sh (+0.46%)
Ken Fisher 549,908 sh (+0.12%)
Chuck Royce 56,100 sh (unchged)
Jim Simons 110,000 sh (-25.78%)
» More
Q3 2016

CHE Guru Trades in Q3 2016

Chuck Royce 56,100 sh (unchged)
Keeley Asset Management Corp 15,985 sh (unchged)
Ken Fisher 549,286 sh (-0.11%)
Mario Gabelli 635,572 sh (-1.31%)
Jim Simons 94,800 sh (-13.82%)
Joel Greenblatt 87,824 sh (-17.87%)
Jeremy Grantham 77,755 sh (-32.31%)
» More
» Details

Insider Trades

Latest Guru Trades with CHE

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Health Care Providers » Medical Care    NAICS: 621610    SIC: 8082
Compare:OTCPK:LTGHY, NAS:LPNT, NAS:SCAI, NYSE:SEM, NYSE:THC, NYSE:AMN, NAS:ACHC, NAS:AMED, NAS:AMSG, NAS:PAHC, NYSE:HLS, NAS:HWAY, NAS:LHCG, NAS:SGRY, NYSE:USPH, NYSE:CYH, OTCPK:RLGHF, NAS:PRSC, NAS:AFAM, OTCPK:MFCSF » details
Traded in other countries:CXM.Germany,
Chemed Corp through its subsidiaries, operates in the healthcare and plumbing business in the United States. The Company's business segments include VITAS segment (VITAS) and the Roto-Rooter segment (Roto-Rooter).

Chemed Corp was incorporated in Delaware in 1970. The Company conducts its business operations in two segments: the VITAS segment (VITAS) and the Roto-Rooter segment (Roto-Rooter). VITAS Healthcare Corporation provides hospice and palliative care services to its patients through a network of physicians, registered nurses, home health aides, social workers, clergy and volunteers. Roto-Rooter provides plumbing and drain cleaning services to both residential and commercial customers. Roto-Rooter has manufacturing and distribution center facilities in West Des Moines, Iowa and has 109 leased and owned office and service facilities in 30 states. VITAS operate 51 programs from 154 leased facilities and 37 inpatient units in 18 states and the District of Columbia. The Company faces competition from sewer, drain and pipe cleaning, excavation and plumbing repair businesses and is fragmented, with the bulk of the industries consisting of local and regional competitors. VITAS competes with a number of national and regional hospice providers, including Gentiva Health Services, Inc., hospitals, nursing homes, home health agencies and other health care providers. The Company is subject to federal, state and local laws and regulations relating to franchising, insurance and other aspects of business.

Ratios

vs
industry
vs
history
P/E(ttm) 24.71
CHE's P/E(ttm) is ranked higher than
54% of the 194 Companies
in the Global Medical Care industry.

( Industry Median: 25.07 vs. CHE: 24.71 )
Ranked among companies with meaningful P/E(ttm) only.
CHE' s P/E(ttm) Range Over the Past 10 Years
Min: 10.72  Med: 18.28 Max: 41.85
Current: 24.71
10.72
41.85
Forward P/E 19.76
CHE's Forward P/E is ranked lower than
66% of the 53 Companies
in the Global Medical Care industry.

( Industry Median: 16.18 vs. CHE: 19.76 )
Ranked among companies with meaningful Forward P/E only.
N/A
PE(NRI) 24.71
CHE's PE(NRI) is ranked higher than
54% of the 194 Companies
in the Global Medical Care industry.

( Industry Median: 25.14 vs. CHE: 24.71 )
Ranked among companies with meaningful PE(NRI) only.
CHE' s PE(NRI) Range Over the Past 10 Years
Min: 10.75  Med: 17.94 Max: 40.94
Current: 24.71
10.75
40.94
Price/Owner Earnings (ttm) 20.68
CHE's Price/Owner Earnings (ttm) is ranked higher than
66% of the 88 Companies
in the Global Medical Care industry.

( Industry Median: 25.79 vs. CHE: 20.68 )
Ranked among companies with meaningful Price/Owner Earnings (ttm) only.
CHE' s Price/Owner Earnings (ttm) Range Over the Past 10 Years
Min: 8.41  Med: 18 Max: 137.98
Current: 20.68
8.41
137.98
P/B 5.17
CHE's P/B is ranked lower than
80% of the 231 Companies
in the Global Medical Care industry.

( Industry Median: 2.39 vs. CHE: 5.17 )
Ranked among companies with meaningful P/B only.
CHE' s P/B Range Over the Past 10 Years
Min: 1.89  Med: 2.9 Max: 5.48
Current: 5.17
1.89
5.48
P/S 1.68
CHE's P/S is ranked lower than
55% of the 238 Companies
in the Global Medical Care industry.

( Industry Median: 1.45 vs. CHE: 1.68 )
Ranked among companies with meaningful P/S only.
CHE' s P/S Range Over the Past 10 Years
Min: 0.67  Med: 1.06 Max: 1.82
Current: 1.68
0.67
1.82
PFCF 18.35
CHE's PFCF is ranked higher than
67% of the 103 Companies
in the Global Medical Care industry.

( Industry Median: 23.72 vs. CHE: 18.35 )
Ranked among companies with meaningful PFCF only.
CHE' s PFCF Range Over the Past 10 Years
Min: 7.31  Med: 14.38 Max: 81.99
Current: 18.35
7.31
81.99
POCF 14.04
CHE's POCF is ranked higher than
55% of the 152 Companies
in the Global Medical Care industry.

( Industry Median: 14.12 vs. CHE: 14.04 )
Ranked among companies with meaningful POCF only.
CHE' s POCF Range Over the Past 10 Years
Min: 6.07  Med: 10.82 Max: 29.92
Current: 14.04
6.07
29.92
EV-to-EBIT 14.69
CHE's EV-to-EBIT is ranked higher than
69% of the 190 Companies
in the Global Medical Care industry.

( Industry Median: 19.66 vs. CHE: 14.69 )
Ranked among companies with meaningful EV-to-EBIT only.
CHE' s EV-to-EBIT Range Over the Past 10 Years
Min: 7.1  Med: 10.7 Max: 21.9
Current: 14.69
7.1
21.9
EV-to-EBITDA 12.40
CHE's EV-to-EBITDA is ranked higher than
63% of the 202 Companies
in the Global Medical Care industry.

( Industry Median: 14.51 vs. CHE: 12.40 )
Ranked among companies with meaningful EV-to-EBITDA only.
CHE' s EV-to-EBITDA Range Over the Past 10 Years
Min: 5.9  Med: 8.8 Max: 17
Current: 12.4
5.9
17
PEG 2.49
CHE's PEG is ranked higher than
55% of the 82 Companies
in the Global Medical Care industry.

( Industry Median: 2.64 vs. CHE: 2.49 )
Ranked among companies with meaningful PEG only.
CHE' s PEG Range Over the Past 10 Years
Min: 0.3  Med: 1.26 Max: 2.75
Current: 2.49
0.3
2.75
Shiller P/E 34.60
CHE's Shiller P/E is ranked lower than
60% of the 45 Companies
in the Global Medical Care industry.

( Industry Median: 27.06 vs. CHE: 34.60 )
Ranked among companies with meaningful Shiller P/E only.
CHE' s Shiller P/E Range Over the Past 10 Years
Min: 22.86  Med: 33.31 Max: 76.53
Current: 34.6
22.86
76.53
Current Ratio 0.79
CHE's Current Ratio is ranked lower than
78% of the 252 Companies
in the Global Medical Care industry.

( Industry Median: 1.28 vs. CHE: 0.79 )
Ranked among companies with meaningful Current Ratio only.
CHE' s Current Ratio Range Over the Past 10 Years
Min: 0.57  Med: 1.16 Max: 1.88
Current: 0.79
0.57
1.88
Quick Ratio 0.76
CHE's Quick Ratio is ranked lower than
76% of the 252 Companies
in the Global Medical Care industry.

( Industry Median: 1.15 vs. CHE: 0.76 )
Ranked among companies with meaningful Quick Ratio only.
CHE' s Quick Ratio Range Over the Past 10 Years
Min: 0.56  Med: 1.08 Max: 1.79
Current: 0.76
0.56
1.79
Days Inventory 2.05
CHE's Days Inventory is ranked higher than
91% of the 184 Companies
in the Global Medical Care industry.

( Industry Median: 18.12 vs. CHE: 2.05 )
Ranked among companies with meaningful Days Inventory only.
CHE' s Days Inventory Range Over the Past 10 Years
Min: 2.05  Med: 3.08 Max: 3.3
Current: 2.05
2.05
3.3
Days Sales Outstanding 19.97
CHE's Days Sales Outstanding is ranked higher than
77% of the 211 Companies
in the Global Medical Care industry.

( Industry Median: 42.10 vs. CHE: 19.97 )
Ranked among companies with meaningful Days Sales Outstanding only.
CHE' s Days Sales Outstanding Range Over the Past 10 Years
Min: 16.39  Med: 28.15 Max: 33.57
Current: 19.97
16.39
33.57
Days Payable 14.06
CHE's Days Payable is ranked lower than
82% of the 164 Companies
in the Global Medical Care industry.

( Industry Median: 38.65 vs. CHE: 14.06 )
Ranked among companies with meaningful Days Payable only.
CHE' s Days Payable Range Over the Past 10 Years
Min: 14.06  Med: 20.06 Max: 24.87
Current: 14.06
14.06
24.87

Dividend & Buy Back

vs
industry
vs
history
Dividend Yield 0.65
CHE's Dividend Yield is ranked lower than
87% of the 243 Companies
in the Global Medical Care industry.

( Industry Median: 1.60 vs. CHE: 0.65 )
Ranked among companies with meaningful Dividend Yield only.
CHE' s Dividend Yield Range Over the Past 10 Years
Min: 0.35  Med: 0.73 Max: 1.2
Current: 0.65
0.35
1.2
Dividend Payout 0.16
CHE's Dividend Payout is ranked higher than
98% of the 137 Companies
in the Global Medical Care industry.

( Industry Median: 0.38 vs. CHE: 0.16 )
Ranked among companies with meaningful Dividend Payout only.
CHE' s Dividend Payout Range Over the Past 10 Years
Min: 0.07  Med: 0.16 Max: 11
Current: 0.16
0.07
11
Dividend Growth (3y) 10.60
CHE's Dividend Growth (3y) is ranked lower than
56% of the 71 Companies
in the Global Medical Care industry.

( Industry Median: 17.10 vs. CHE: 10.60 )
Ranked among companies with meaningful Dividend Growth (3y) only.
CHE' s Dividend Growth (3y) Range Over the Past 10 Years
Min: -42.4  Med: 2.9 Max: 35.7
Current: 10.6
-42.4
35.7
Forward Dividend Yield 0.67
CHE's Forward Dividend Yield is ranked lower than
88% of the 233 Companies
in the Global Medical Care industry.

( Industry Median: 1.66 vs. CHE: 0.67 )
Ranked among companies with meaningful Forward Dividend Yield only.
N/A
Yield on cost (5-Year) 1.15
CHE's Yield on cost (5-Year) is ranked lower than
74% of the 307 Companies
in the Global Medical Care industry.

( Industry Median: 2.27 vs. CHE: 1.15 )
Ranked among companies with meaningful Yield on cost (5-Year) only.
CHE' s Yield on cost (5-Year) Range Over the Past 10 Years
Min: 0.62  Med: 1.29 Max: 2.11
Current: 1.15
0.62
2.11
3-Year Average Share Buyback Ratio 3.20
CHE's 3-Year Average Share Buyback Ratio is ranked higher than
94% of the 127 Companies
in the Global Medical Care industry.

( Industry Median: -2.50 vs. CHE: 3.20 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
CHE' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -9.8  Med: 1.9 Max: 6.4
Current: 3.2
-9.8
6.4

Valuation & Return

vs
industry
vs
history
Price/Projected FCF 1.45
CHE's Price/Projected FCF is ranked higher than
60% of the 94 Companies
in the Global Medical Care industry.

( Industry Median: 1.64 vs. CHE: 1.45 )
Ranked among companies with meaningful Price/Projected FCF only.
CHE' s Price/Projected FCF Range Over the Past 10 Years
Min: 0.64  Med: 1.29 Max: 2.33
Current: 1.45
0.64
2.33
Price/DCF (Earnings Based) 1.31
CHE's Price/DCF (Earnings Based) is ranked higher than
65% of the 31 Companies
in the Global Medical Care industry.

( Industry Median: 1.57 vs. CHE: 1.31 )
Ranked among companies with meaningful Price/DCF (Earnings Based) only.
N/A
Price/Median PS Value 1.58
CHE's Price/Median PS Value is ranked lower than
79% of the 195 Companies
in the Global Medical Care industry.

( Industry Median: 1.00 vs. CHE: 1.58 )
Ranked among companies with meaningful Price/Median PS Value only.
CHE' s Price/Median PS Value Range Over the Past 10 Years
Min: 0.57  Med: 0.96 Max: 1.66
Current: 1.58
0.57
1.66
Price/Peter Lynch Fair Value 2.84
CHE's Price/Peter Lynch Fair Value is ranked lower than
62% of the 42 Companies
in the Global Medical Care industry.

( Industry Median: 2.54 vs. CHE: 2.84 )
Ranked among companies with meaningful Price/Peter Lynch Fair Value only.
CHE' s Price/Peter Lynch Fair Value Range Over the Past 10 Years
Min: 0.5  Med: 1.36 Max: 5.14
Current: 2.84
0.5
5.14
Earnings Yield (Greenblatt) (%) 6.81
CHE's Earnings Yield (Greenblatt) (%) is ranked higher than
77% of the 240 Companies
in the Global Medical Care industry.

( Industry Median: 3.80 vs. CHE: 6.81 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) (%) only.
CHE' s Earnings Yield (Greenblatt) (%) Range Over the Past 10 Years
Min: 4.6  Med: 9.4 Max: 14.1
Current: 6.81
4.6
14.1
Forward Rate of Return (Yacktman) (%) 12.95
CHE's Forward Rate of Return (Yacktman) (%) is ranked higher than
61% of the 113 Companies
in the Global Medical Care industry.

( Industry Median: 10.28 vs. CHE: 12.95 )
Ranked among companies with meaningful Forward Rate of Return (Yacktman) (%) only.
CHE' s Forward Rate of Return (Yacktman) (%) Range Over the Past 10 Years
Min: 12.95  Med: 19.9 Max: 57.5
Current: 12.95
12.95
57.5

More Statistics

Revenue (TTM) (Mil) $1,572
EPS (TTM) $ 6.27
Beta1.46
Short Percentage of Float10.75%
52-Week Range $124.77 - 158.24
Shares Outstanding (Mil)16.22

Analyst Estimate

Dec16 Dec17
Revenue (Mil $) 1,582 1,647
EPS ($) 7.23 7.82
EPS w/o NRI ($) 7.23 7.82
EPS Growth Rate
(3Y to 5Y Estimate)
10.00%
Dividends Per Share ($)
» More Articles for NYSE:CHE

Headlines

Articles On GuruFocus.com
John Hussman Sells Broadcom, Cognizant May 13 2016 
Mario Gabelli Comments on Chemed Corp. Jan 29 2014 
The Gabelli Asset Fund Shareholder Commentary - Fourth Quarter 2013 Jan 29 2014 
3 Cheap Health Care Dividend Stocks with Huge Potential to Grow Dividends Oct 02 2013 
Chemed Corporation: Fundamental Stock Research Analysis Jan 29 2013 
12 Healthcare Dividend Stocks With Highest Short Float Ratio Jun 02 2012 
9 Dividend Stocks Raising Their Yield On Cost Aug 15 2011 
Guru Stocks Raising Dividends: THO, ACU, KAMN, PRIM, CHE Aug 15 2011 
Chemed Corp. Reports Operating Results (10-K) Feb 28 2011 
Chemed Corp. Reports Operating Results (10-Q) Nov 03 2010 

More From Other Websites
Do Hedge Funds Love Sterling Bancorp (STL)? Dec 08 2016
Is Chemed Corporation (CHE) Going to Burn These Hedge Funds? Dec 03 2016
ETFs with exposure to Chemed Corp. : November 14, 2016 Nov 14 2016
Chemed Corp. :CHE-US: Earnings Analysis: Q3, 2016 By the Numbers : November 10, 2016 Nov 10 2016
CHEMED CORP Financials Nov 04 2016
Chemed Corporation Declares Quarterly Dividend of 26 Cents Nov 04 2016
Chemed Corporation Declares Quarterly Dividend of 26 Cents Nov 04 2016
Chemed Corporation to Present at the 2016 Credit Suisse Healthcare Conference Nov 01 2016
CHEMED CORP Files SEC form 10-Q, Quarterly Report Nov 01 2016
Chemed (CHE) Lags Q3 Earnings, Tops Sales; EPS View Up Oct 28 2016
Edited Transcript of CHE earnings conference call or presentation 27-Oct-16 2:00pm GMT Oct 27 2016
Chemed Corp Earnings Call scheduled for 10:00 am ET today Oct 27 2016
Chemed Corp. breached its 50 day moving average in a Bearish Manner : CHE-US : October 27, 2016 Oct 27 2016
Chemed posts 3Q profit Oct 26 2016
Chemed posts 3Q profit Oct 26 2016
Chemed Reports Third-Quarter 2016 Results Oct 26 2016
CHEMED CORP Files SEC form 8-K, Results of Operations and Financial Condition Oct 26 2016
Chemed Reports Third-Quarter 2016 Results Oct 26 2016
The Zacks Analyst Blog Highlights: Universal Health Services, VCA, Chemed and PAREXEL International Oct 26 2016
Q3 2016 Chemed Corp Earnings Release - After Market Close Oct 26 2016

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)